Viridian Therapeuticsincis A Biopharmaceutical Company Based In Walthammassachusettsfounded In 2006Formerly Known As Miragen Therapeuticsthe Company Rebranded In January 2021Viridian Is Dedicated To Discoveringdevelopingand Commercializing Treatments For Serious And Rare Diseasesutilizing Its Expertise In Antibody Discovery And Protein Engineering The Companyae S Product Pipeline Includes Veligrotugvrdn 001 A Monoclonal Antibody In Phase 3 Clinical Trials For Thyroid Eye Diseaseand Vrdn 003A Next Generation Igf 1R Monoclonal Antibody Also In Phase 3 Trials For The Same Conditionadditionallyviridian Is Developing A Portfolio Of Engineered Anti Fcrn Inhibitorssuch As Vrdn 006 And Vrdn 008Aimed At Treating Various Autoimmune Diseasesviridian S Mission Is To Deliver Transformative Therapies For Patients With Underserved Diseasesemphasizing Innovation And Patient Centricity
No conferences found for this company.
| Company Name | Miragen Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
